- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03653117
Transperineal Laser Ablation for Treatment of Benign Prostatic Obstruction
Transperineal Laser Ablation for Treatment of LUTS Due to Benign Prostatic Obstruction
Rationale: With age a large group of men experience lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO). Standard treatment is a transurethral resection of the prostate or laser vaporization. As these techniques enter the prostate via the urethra, are invasive and require general or spinal anaesthesia. Transperineal laser ablation (TPLA) is a minimal invasive procedure, that can be performed under local anaesthesia.
Objective: The primary objective of this study is to prove feasibility and safety of TPLA for LUTS due to BPO in healthy men.
Secondary objectives: The secondary objectives are to determine functional voiding, erectile outcomes and changes on imaging.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is set up as a prospective, single centre, interventional pilot study.
Eligible patients are diagnosed with LUTS due to BPO at the outpatient clinic of the department of Urology at the Academic Medical Center (AMC) and have an indication for surgical treatment. The investigators aim to include 20 patients.
Eligible patients will be informed about this study by the urologist in the outpatient clinic. Information about the study will be provided both orally and in written form.
The TPLA procedure is performed with the Echolaser X4 system. The system uses a diode laser source that operates at the 1064nm wavelength. The maximum energy delivered is 10 watts per laser source. The system works with the concept of thermoablation, resulting in coagulative necrosis of tissue. Two to four fibers are introduced in the prostate under untrasound vision. Ablation will be performed with 3 watts power per fibre and a total of 1200 - 1800 J will be delivered per fibre in 400 - 600 s.
Follow-up will exist of four visits following surgery at 4 weeks, three, six and 12 months. The visits imply medical history, adverse event registration, physical examination (on indication) and uroflowmetry. Patient-reported outcome measures (PROMs) are used to measure functional outcomes. Used PROMs are the International Prostate Symptom Score (IPSS), International Index of Erectile Function 15 (IIEF-15), Visual Analogue Scale (VAS) and hematuria grading scale (HGS). In addition to this, imaging will exist of a contrast enhanced ultrasound (CEUS) at four weeks and 12 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1105AZ
- Academic Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male
- ≥ 40 years of age
- Peak urinary flow rate (Qmax): ≥ 5 mL/sec to ≤ 15 mL/sec, with a minimum voided volume of ≥ 125 mL, measured with uroflowmetry or urodynamic investigation
- Post-void residual (PVR): ≤ 250 mL
- Prostate volume: ≥ 30 and ≤ 120 cc, measured by transrectal ultrasound
- Urodynamic investigation proven bladder outlet obstruction
- Signed informed consent
Exclusion Criteria:
- Previous invasive prostate intervention (TURP, laser, ablation, etc.)
- History of prostate or bladder cancer
- Indwelling Foley catheter or clean intermittent catheterization (CIC)
- PSA of ≥ 3.0 ng/mL without negative biopsies
- Inability or unwillingness to tolerate temporary discontinuation of anticoagulation or anti-platelet therapy
Other conditions / status
- Active urinary tract infection / prostatitis
- Macroscopic haematuria without a known contributing factor
- Poor detrusor muscle function or other neurological disorder that would impact bladder function (eg, multiple sclerosis, Parkinson's disease, spinal cord injuries, (diabetic) polyneuropathy)
- Concurrent malignancy except basal skin cancer
- History of lower urinary tract surgery (eg, TURP, laser, urinary diversion, artificial urinary sphincter, penile prosthesis)
- History of pelvic radiation therapy or radical pelvic surgery
- History of bladder neck contracture and/or urethral strictures within the 5 years prior to the informed consent date
- Bladder stones
- Medical contraindication for undergoing TPLA surgery (eg, infection, coagulopathy, significant cardiac or other medical risk factors for surgery)
- Diagnosed or suspected bleeding disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TPLA
TPLA procedure
|
Minimal invasive coagulation of prostatic tissue by laser
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of technical successful TPLA treatments
Time Frame: 24 hours following TPLA treatment
|
Number of technical successful performed TPLA treatments without failures related to the machine or procedure.
|
24 hours following TPLA treatment
|
Incidence of TPLA treatment-emergent adverse events
Time Frame: 30 days following TPLA treatment
|
Number of adverse events using the CTCAE v5.0.
Procedural safety is shown when there are no adverse events of grade 3 or higher.
|
30 days following TPLA treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional outcomes of TPLA
Time Frame: 12 months following TPLA treatment
|
Functional outcomes of TPLA measured by uroflowmetry, expressed in change of Qmax.
|
12 months following TPLA treatment
|
Spontaneous voiding post TPLA
Time Frame: 24 hours following TPLA treatment
|
The presence of spontaneous voiding following TPLA treatment
|
24 hours following TPLA treatment
|
Erectile function
Time Frame: 12 months following TPLA treatment
|
To evaluate erectile function after TPLA treatment, measured by the International Index of Erectile function 15 (IIEF-15) IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; Erectile function: Q1-5 Score range 0-5 + Q15 score range 1-5, total score 1-30, higher indicates better outcome; Orgasmic function: Q9-10 Score range 0-5, total score 0-10, higher indicates better outcome; Sexual desire: Q11-12 Score range 1-5, total score 2-10, higher indicates better outcome; Intercourse satisfaction: Q6-8 Score range 0-5, total score 0-15, higher indicates better outcome; Overall satisfaction: Q13-14 Score range 1-5, total score 2-10, higher indicates better outcome; All subscale are summed to combine them to a total IIEF-15 score.
|
12 months following TPLA treatment
|
Antegrade ejaculation
Time Frame: 12 months following TPLA treatment
|
To evaluate antegrade ejaculation after TPLA treatment, measured by patient reporting.
|
12 months following TPLA treatment
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018_149
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia, Benign
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
Clinical Trials on Transperineal laser ablation
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
-
San Carlo di Nancy HospitalElesta S.R.L.Recruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingProstate CancerNetherlands
-
University of Rome Tor VergataRecruitingLower Urinary Tract Symptoms | Benign Prostatic HyperplasiaItaly
-
University of Rome Tor VergataEuropean Institute of Oncology; Ospedale Regina ApostolorumUnknownLower Urinary Tract Symptoms | BPHItaly
-
University of Rome Tor VergataRecruitingProstate CancerItaly
-
Urological Research Network, LLCRecruitingMRI | Urinary Incontinence | Prostate Cancer | Ultrasound | Ablation | Sexual Function Disturbances | Prostate Biopsy | Adverse Effects Surgery | Urinary Function DisordersUnited States
-
Mayo ClinicRecruitingProstate Cancer | Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8United States
-
Hospital Clinic of BarcelonaCardioFocusCompleted
-
Jonsson Comprehensive Cancer CenterMedtronic; Jean Perkins FoundationCompleted